This study is a component of an initial stage of at least 10 Phase I and II clinical trials of IMC-A12 sponsored by the cancer therapy evaluation program of the division of cancer treatment and diagnosis at the National Cancer Institute (NCI), to commence patient enrollment. ImClone announced the selection of these proposals by NCI in September 2007.
Eric Rowinsky, chief medical officer and executive vice president of ImClone, said: “This NCI-sponsored IMC-A12 trial is based on preclinical evidence that the mTOR and IGF-1R growth and survival signaling pathways are intimately linked and, therefore, the combination of IMC-A12 and temsirolimus may be an ideal means to optimize treatment.”